Action Center

Action Center

Tell FDA: Patients Deserve Safe, Regulated GLP-1 Medicines

The U.S. Food and Drug Administration has proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List after concluding that there is no clinical need for outsourcing facilities to compound these drugs from bulk substances.This proposal is an...

Support CA AB 1990 to Protect Patients from Unsafe Compounded Weight-Loss Drugs

California patients deserve access to safe, effective, and properly regulated medications.AB 1990 would establish important consumer protection and safety standards for compounded GLP-1 and related weight-loss medications in California. As demand for these medications...

Take Action: Preserve Access to Life-Changing Obesity Medications

Massachusetts patients are at risk of losing access to critical obesity treatment medications.GLP-1 medications are FDA-approved treatments that help patients manage obesity and reduce the risk of serious chronic diseases including type 2 diabetes, heart disease,...

Protect Kidney Patient Stability & Transplant Readiness in NY

Protecting Kidney Patient Stability & Transplant Readiness in NY Unfortunately, kidney patients already face systemic barriers to equitable care and transplantation. Now is the time to ensure decision makers are protecting patients - many of them...